Efgartigimod Better Than Placebo at Easing gMG Symptoms: ADAPT Trial

Efgartigimod Better Than Placebo at Easing gMG Symptoms: ADAPT Trial

309154

Efgartigimod Better Than Placebo at Easing gMG Symptoms: ADAPT Trial

More adults with generalized myasthenia gravis (gMG) who were treated with efgartigimod in a Phase 3 trial experienced minimal or no symptoms than did those given a placebo, an analysis of new study data reported. Other analyses from the ADAPT trial highlighted the potential benefits of efgartigimod for people who are negative for the most common type of disease-causing antibody seen in MG. “The additional ADAPT data … strengthen our understanding of the value efgartigimod can offer as…

You must be logged in to read/download the full post.